BioTime, Inc (Amex: BTX) develops blood plasma volume expanders and blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Read more…
Pluristem Therapeutics (NASDAQ: PSTI) is engaged in the production, research and development of placental-derived adherent stromal cells (ASCs). PSTI commercializes non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic and autoimmune disorders. Focus: PSTI develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in proprietary PluriXTM 3 dimensional bio-reactors; which imitates the natural micro-structure of bone marrow and does not require supplemental growth factors or other exogenous materials. Read more…
Osiris Therapeutics (NASDAQ: OSIR) has focused on the advancement of mesenchymal stem cell (MSC) technologies and is focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. Focus: OSIR’s principal product(s) include Prochymal, for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn’s disease, and acute radiation syndrome; treatment of Type I diabetes mellitus, acute myocardial infarction, chronic obstructive pulmonary disease and Chondrogen, a treatment of osteoarthritis and the reduction of pain in the knee.
During the second week of January, Unilife Medical Solutions (ASX: UNI.AX) (OTC: UNIFF.PK) shareholders overwhelmingly voted in favor of the Company’s U.S. relocation. Unilife is now in the final stages of preparation for a NASDAQ: UNIS stock market trading debut, which is expected to occur by the end of February in conjunction with the Company’s re-domiciliation to Central Pennsylvania. Unilife is emerging as a leading innovator in the medical device manufacturing space with a focus on safety syringes and business segments that include pre-filled syringes for pharmaceutical companies to deliver injected medications, sharps safety devices for healthcare facilities, and contract manufacturing services.
There are 337 (276 public and 61 private) lifescience companies presenting starting Monday, 1/11 and running through Thursday, 1/14. Link: JPMHealthcareConference-Agenda1.7
Public company presentations are usually web-cast enabling non-participants to view presentations with breakout sessions immediately following their presentations. These web-casts will be available for 3 months after the conference: https://events.jpmorgan.com/ ; so click on the web-cast link (no need for a user name and password but will be prompted an email address). As related to current economic times, registration of attendees was limited by JP Morgan to a total of about 3,500 versus 6,000 in the past years.
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA. Read more…
Delcath Systems (NASDAQ: DCTH) is an emerging, small-cap medical device innovator that is developing a regional treatment system for cancer in the liver. Delcath’s Percutaneous Hepatic Perfusion (PHP) technology allows physicians to deliver significantly higher doses of existing chemotherapy drugs to the liver without exposing each patient’s entire body to the anti-cancer drugs, representing an elegant solution that promises to increase the effectiveness of approved anti-cancer drugs while reducing systemic side effects. Read more…
The FDA has granted Cytori marketing clearance for the PureGraft™ System. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.